Aristotle University Of Thessaloniki (AUTH)
Η επίδραση της bevacizumab στις ενδοκοιλιακές μετεγχειρητικές συμφύσεις: πειραματική μελέτη σε επίμυες
Abstract
dc:descriptionPostoperative peritoneal adhesions are among the most frequent and grave complications of abdominal surgery. They can cause bowel obstruction, chronic pelvic pain, infertility and difficulties in subsequent operations, by increasing operating times and risk of splanchnic injury. Their increased incidence and their consequences are the reasons for the continuous research for an efficient and safe antiadhesive agent. Up to now, a large number of different medicines and methods have been tested. In this study, we evaluated the efficacy of bevacizumab in the prevention of peritoneal postoperative adhesions. For this purpose, 90 Wistar Albino male rats were randomly allocated to three groups. Group one received bevacizumab (group BE), group two received normal saline (group P) and group three was the sham group. Each group was further divided into three subgroups, according to reoperation day. The subjects in group one underwent abrasion of the cecum wall with a dry gauze and intraperitoneal instillation of bevacizumab, at a dosage of 5mg/Kg. The subjects in group two underwent the same procedure and received intraperitoneal normal saline in the same dosage and the subjects in group three did not undergo any procedure. Reoperation was performed in postoperative days 2, 14 and 28. (Subgroups ΒΕ-2, ΒΕ-14, ΒΕ-28 και Ρ-2, Ρ-14, Ρ-28) At re-operation, two blinded to the study-groups surgeons clinically assessed the adhesions according to a predetermined scale. Tissue and blood samples for laboratory measurements of tissue plasminogen activator (tPA), plasminogen activator inhibitor -1(PAI-1) and metalloproteinase-9 (MMP-9) and for histopathological assessment were obtained. Adhesions were clinically less, in extent and severity in all the bevacizumab sub-groups. In addition, tPA concentrations in tissue samples were higher in all the study sub-groups. PAI-1 concentrations were significantly lower in peritoneum samples in subgroups BE-2 and BE-14 and in cecum samples in all the BE subgroups. MMP-9 concentrations were higher in tissue samples in all the BE subgroups and in blood samples of group BE-14 compared to P-14. Histopathological analysis demonstrated differences in fibrosis and angiogenesis in the subgroups of postoperative days 14 and 28.Our findings show that intraperitoneal instillation of a single therapeutic dose of bevacizumab can reduce postoperative peritoneal adhesions. This action seems to start in the early postoperative period and continues until the 28th postoperative day.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Micha, Aikaterini-Eftychia
- Μίχα, Αικατερίνη-Ευτυχία
Subjects
dc:subject × 16- Μπεβασιζουμάμπη
- Περιτοναϊκές συμφύσεις
- Ιστικός ενεργοποιητής του πλασμινογόνου
- Αναστολέας του ιστικού ενεργοποιητή του πλασμινογόνου
- Αγγειακός ενδοθηλιακός αυξητικός παράγοντας (VEGF)
- Μεταλλοπρωτεϊνάσες εξωκυττάριου δικτύου
- Bevacizumab
- Peritoneal adhesions
- Tissue plasminogen activator
- Plasminogen activator inhibitor
- Vascular endothelial growth factor
- Matrix metalloproteinases
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42206